SANGAMO THERAPEUTICS, INC. SGMO Income Statement

Sangamo therapeutics, inc. (SGMO)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
Revenues
107,433	102,428	74,414	76,018	79,886	84,452	70,692	58,942	45,779	36,567	32,412	23,423	18,872	19,389	19,588	25,334	29,990	39,539	45,370	49,218	51,245	45,870	37,787	31,077	27,626	24,133	26,196	25,396	23,036	21,655	17,471	14,421	11,361	10,319	8,514	13,182	0	0	0
Operating expenses:
Research and development
152,551	145,922	140,847	133,369	126,169	114,866	100,989	90,604	76,333	65,728	60,241	58,824	63,294	65,618	71,634	71,320	67,484	67,198	62,383	62,029	59,871	56,974	52,721	45,084	40,902	37,039	35,483	34,350	32,646	31,709	30,305	30,574	31,119	32,098	32,989	32,297	0	0	0
General and administrative
60,687	61,686	60,988	57,063	53,767	46,736	39,847	35,276	30,012	27,200	24,596	23,195	28,248	26,330	26,356	25,895	19,822	19,197	18,639	17,810	16,765	15,677	15,552	14,984	14,136	13,800	12,614	12,590	12,210	12,144	12,360	12,813	13,745	14,042	13,696	13,361	0	0	0
Total operating expenses
213,238	207,608	201,835	190,432	179,936	161,602	140,836	125,880	106,345	92,928	84,837	82,019	91,542	91,948	97,990	97,215	87,306	86,395	81,022	79,839	76,636	72,651	68,273	60,068	55,038	50,839	48,097	46,940	44,856	43,853	42,665	43,387	44,864	46,140	46,685	45,658	0	0	0
Loss from operations
-105,805	-105,180	-127,421	-114,414	-100,050	-77,150	-70,144	-66,938	-60,566	-56,361	-52,425	-58,596	-72,670	-72,559	-78,402	-71,881	-57,316	-46,856	-35,652	-30,621	-25,391	-26,781	-30,486	-28,991	-27,412	-26,706	-21,901	-21,544	-21,820	-22,198	-25,194	-28,966	-33,503	-35,821	-38,171	-32,476	0	0	0
Interest and other income, net
9,615	9,761	8,282	9,793	9,145	8,261	7,383	4,666	2,443	1,793	1,337	894	860	887	693	556	464	431	556	564	479	364	244	149	101	82	0	-59	-61	-	49	57	63	-	-	-	-	-	-
Loss before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-46,425	-35,096	-30,057	-24,912	-26,417	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Benefit from income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-5,722	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-96,190	-95,419	-119,139	-104,621	-90,905	-68,889	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to non-controlling interest
-241	-233	-179	-125	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71	85	84	0	0	0
Net loss to Sangamo Therapeutics, Inc. stockholders
-95,949	-95,186	-118,405	-103,941	-90,297	-68,334	-62,761	-62,272	-58,123	-54,568	-51,101	-57,712	-71,796	-71,658	-76,047	-66,327	-51,878	-40,703	-31,009	-29,309	-24,164	-26,417	-30,242	-28,842	-27,311	-26,624	-21,958	-21,603	-21,881	-22,264	-25,145	-28,909	-33,440	-35,750	-38,086	-32,392	0	0	0
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)
-0.37	0.04	-0.24	-0.26	-0.41	-0.17	-0.13	-0.17	-0.23	-0.15	-0.15	-0.17	-0.23	-0.14	-0.27	-0.38	-0.23	-0.20	-0.13	-0.17	-0.08	-0.06	-0.11	-0.10	-0.12	-0.14	-0.11	-0.10	-0.13	-0.06	-0.11	-0.11	-0.14	-0.12	-0.18	-0.20	-0.21	-0.19	-0.09
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)
116,060	116,094	115,710	114,382	102,270	102,438	101,725	97,267	86,334	85,034	83,750	72,527	71,025	70,734	70,618	70,487	70,373	70,169	69,892	69,684	69,283	68,679	68,230	67,980	63,199	61,947	54,786	53,786	53,377	52,972	52,768	52,657	52,567	52,623	52,464	51,500	45,461	45,201	45,157
Net loss
-95,949	-95,186	-118,405	-103,941	-90,297	-68,334	-62,761	-62,272	-58,123	-54,568	-60,442	-74,663	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Changes in unrealized gain (loss) on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-
Collaboration Agreements [Member]
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	18,476	18,881	18,997	24,675	28,884	37,844	43,424	47,063	48,983	43,880	35,947	28,727	25,163	21,678	23,586	22,951	20,606	18,186	12,899	9,490	6,286	6,110	5,110	10,539	0	0	0
Research Grants [Member]
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	396	508	591	659	1,106	1,695	1,946	2,155	2,262	1,990	1,840	2,350	2,463	2,455	2,610	2,445	2,430	3,469	4,572	4,931	5,075	4,209	3,404	2,643	0	0	0